To have a big pharma partner end a collaboration or not exercise an option on a lead product are not the death knells they once were for fledgling European biotech companies - at least that’s the experience of a small group of European companies giving their corporate plans a shake-up this autumn.
European Biotechs Mull Going To Market Without Big Pharma Partners
European biotech companies that have lead products turned down by big pharma are now considering the benefits of taking drugs through late-stage development themselves; more funding options, such as concluding an IPO in the U.S. or Europe, is driving some of this change.